Butler Wayne M, Kurko Brian S, Scholl Whitney J, Merrick Gregory S
Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA.
J Contemp Brachytherapy. 2021 Apr;13(2):145-151. doi: 10.5114/jcb.2021.105281. Epub 2021 Apr 14.
To verify the dose sparing effect of hydrogel spacer (SpaceOAR™) on rectal dosimetry for prostate brachytherapy, and to determine whether prostate and rectal dosimetry was affected by the time gap between hydrogel spacer injection and brachytherapy dosimetry.
The Pd brachytherapy dosimetry of 174 consecutive intermediate- and high-risk patients injected with hydrogel was compared with a dosimetry of 174 contemporaneous patients without hydrogel injections. Of the SpaceOAR™ patients, 91 had hydrogel injected upon completion of brachytherapy implant, while the remaining 83 patients had hydrogel placed prior to external beam radiation therapy (EBRT), followed 2-10 weeks later by brachytherapy. Brachytherapy implants were either planned with the prostate undistorted by any hydrogel or planned with hydrogel in place. Dosimetry of the prostate and tissues at risk was determined from CT imaging on the day of brachytherapy implant.
SpaceOAR™ significantly reduced mean and maximum rectal doses as well as rectal wall V, but there was a statistically significant reduction of planning target volume (PTV) D to 121.1% of the prescribed dose in hydrogel patients compared to 123.3% in the non-hydrogel patients. Rectal dosimetry was similar between patients injected with hydrogel after brachytherapy and those with spacer injected prior to EBRT. However, patients who had hydrogel placed prior to EBRT had statistically significantly higher dosimetry indices of PTV and urethra relative to those with spacer placed at the completion of brachytherapy.
There was a significant rectal dose sparing in the cohort with hydrogel spacer compared to a reference group without spacer injection. The rectal dose sparing effect was similar in the sub-group of patients injected with hydrogel prior to EBRT and the sub-group injected with hydrogel at the conclusion of brachytherapy.
验证水凝胶间隔物(SpaceOAR™)对前列腺近距离放射治疗直肠剂量测定的剂量 sparing 效应,并确定水凝胶间隔物注射与近距离放射治疗剂量测定之间的时间间隔是否会影响前列腺和直肠的剂量测定。
将 174 例连续接受水凝胶注射的中高危患者的钯近距离放射治疗剂量测定结果与 174 例同期未接受水凝胶注射患者的剂量测定结果进行比较。在使用 SpaceOAR™的患者中,91 例在近距离放射治疗植入完成后注射水凝胶,其余 83 例患者在体外放射治疗(EBRT)前放置水凝胶,2 - 10 周后进行近距离放射治疗。近距离放射治疗植入计划要么是在前列腺未受任何水凝胶扭曲的情况下制定,要么是在有水凝胶的情况下制定。在近距离放射治疗植入当天,通过 CT 成像确定前列腺和危险组织的剂量测定。
SpaceOAR™显著降低了平均和最大直肠剂量以及直肠壁 V,但与未使用水凝胶的患者相比,使用水凝胶的患者计划靶体积(PTV)D 降至规定剂量的 121.1%,而未使用水凝胶的患者为 123.3%,差异有统计学意义。近距离放射治疗后注射水凝胶的患者与 EBRT 前注射间隔物的患者的直肠剂量测定相似。然而,与在近距离放射治疗完成时放置间隔物的患者相比,在 EBRT 前放置水凝胶的患者的 PTV 和尿道剂量测定指数在统计学上显著更高。
与未注射间隔物的参考组相比,使用水凝胶间隔物的队列中直肠剂量有显著 sparing。在 EBRT 前注射水凝胶的患者亚组和近距离放射治疗结束时注射水凝胶的患者亚组中,直肠剂量 sparing 效应相似。